Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate

• Status: Completed
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the maximum tolerated dose of imatinib mesylate, given in association with a fixed dose of cyclophosphamide (50 mg bid).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Oscar Lambret
• Treatments: Cyclophosphamide; Imatinib Mesylate

Criteria

Inclusion Criteria:

• Rare tumor

• metastatic disease or locally advanced disease, inoperable, with no standard treatment

• At least 28 days since the prior treatment

• Measurable disease with at least one measurable lesion

Exclusion Criteria:

• Medullary insufficiency

• Cystitis, haemorrhagic cystitis

• Hepatic porphyria